MapLight Therapeutics: T. Rowe Price reports 1.7% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MapLight Therapeutics, Inc. (MPLT) was the issuer in an amendment reporting T. Rowe Price Investment Management, Inc.’s beneficial ownership of 945,216 common shares, equal to 1.7% of the class as of September 30, 2026. The reporting person listed sole voting power over 938,725 shares and sole dispositive power over 945,216 shares, with no shared voting or dispositive power.
Key Figures
Key Terms
beneficial ownership regulatory
Sole voting power regulatory
Sole dispositive power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.